Cargando…

Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer

INTRODUCTION: FOLFIRINOX (the combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) is the preferred systemic regimen for locally advanced pancreatic cancer (LAPC). Furthermore, stereotactic body radiation therapy (SBRT) is a promising treatment option for achieving local control i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Jae Hyup, Song, Changhoon, Jung, In Ho, Ahn, Jinwoo, Kim, Bomi, Jung, Kwangrok, Lee, Jong-Chan, Kim, Jaihwan, Hwang, Jin-Hyeok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812488/ https://www.ncbi.nlm.nih.gov/pubmed/36620548 http://dx.doi.org/10.3389/fonc.2022.1050070

Ejemplares similares

Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis
por: Jung, Kwangrok, et al.
Publicado: (2023)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment
por: Jung, Jae Hyup, et al.
Publicado: (2020)

Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer
por: Ahn, Jinwoo, et al.
Publicado: (2022)

Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis
por: Jung, Kwangrok, et al.
Publicado: (2022)

Efficacy improvement in searching MEDLINE database using a novel PubMed visual analytic system: EEEvis
por: Lee, Jong-Chan, et al.
Publicado: (2023)

Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients
por: Shin, Dong Woo, et al.
Publicado: (2021)

Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience
por: Lee, Jongchan, et al.
Publicado: (2018)

Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2021)

Clinical Impact of Unexpected Para-Aortic Lymph Node Metastasis in Surgery for Resectable Pancreatic Cancer
por: Lee, Ho-Kyoung, et al.
Publicado: (2021)

NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer
por: Jung, Kwangrok, et al.
Publicado: (2022)

Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis
por: Lee, Jong-chan, et al.
Publicado: (2018)

Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol
por: Lee, Jong-chan, et al.
Publicado: (2016)

Stereotactic body radiation therapy for locally advanced pancreatic cancer
por: Jung, Jinhong, et al.
Publicado: (2019)

Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience
por: Lee, Hye In, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer after Prior Radiation
por: Sutera, Philip, et al.
Publicado: (2018)

Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery
por: Kim, Mi-Sook, et al.
Publicado: (2015)

Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma
por: Sutera, Philip A., et al.
Publicado: (2018)

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Cost-Effectiveness Results
por: Bijlani, Akash, et al.
Publicado: (2013)

Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
por: Ji, Xiaoqin, et al.
Publicado: (2022)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Janowski, Einsley-Marie, et al.
Publicado: (2015)

One- vs. Three-Fraction Pancreatic Stereotactic Body Radiation Therapy for Pancreatic Carcinoma: Single Institution Retrospective Review
por: Sutera, Philip Anthony, et al.
Publicado: (2017)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer
por: Ji, Xiaoqin, et al.
Publicado: (2021)

Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX
por: Choi, Jin Ho, et al.
Publicado: (2022)

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
por: Ahmed, Kamran A., et al.
Publicado: (2013)

Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases
por: Scouarnec, Cyrielle, et al.
Publicado: (2019)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Shah, Sarthak, et al.
Publicado: (2021)

Clinical Impact of the Administration of FOLFIRINOX Beyond Six Months in Advanced Pancreatic Adenocarcinoma: A Cohort Study
por: Nitipir, Cornelia, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis
por: Shin, Young Seob, et al.
Publicado: (2022)

Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases
por: Shen, Yuxin, et al.
Publicado: (2021)

Stereotactic Body Radiotherapy as an Effective Treatment for Pancreatic Cancer
por: Hurmuz, Pervin, et al.
Publicado: (2023)

Low Incidence of Fatigue after Hypofractionated Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Dash, Chiranjeev, et al.
Publicado: (2012)

Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Esophagectomy for Esophageal Cancer
por: Kim, Juwan, et al.
Publicado: (2022)

Radiation-induced organizing pneumonia after stereotactic body radiotherapy for lung tumor
por: Ochiai, Satoru, et al.
Publicado: (2015)

Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer
por: Blacksburg, Seth R., et al.
Publicado: (2020)

Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer
por: Shen, Feifei, et al.
Publicado: (2022)

Comparing phase‐ and amplitude‐gated volumetric modulated arc therapy for stereotactic body radiation therapy using 3D printed lung phantom
por: Lee, Minsik, et al.
Publicado: (2019)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
por: Carrasquilla, Michael, et al.
Publicado: (2021)

Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer
por: Rana, Zaker, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2r505bu69l5iq8tkbton84db0u